Singular Genomics Systems (NASDAQ:OMIC) Releases Earnings Results, Beats Expectations By $1.33 EPS

Singular Genomics Systems (NASDAQ:OMIC) announced its earnings results on Tuesday. The company reported ($6.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($8.05) by $1.33, Zacks reports. The business had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.74 million. Singular Genomics Systems had a negative return on equity of 54.70% and a negative net margin of 3,237.89%.

Singular Genomics Systems Price Performance

Singular Genomics Systems stock traded down $0.13 during midday trading on Wednesday, hitting $22.84. The stock had a trading volume of 4,996 shares, compared to its average volume of 34,708. The company has a quick ratio of 8.04, a current ratio of 8.77 and a debt-to-equity ratio of 0.05. Singular Genomics Systems has a 12 month low of $5.34 and a 12 month high of $23.41. The business has a fifty day moving average price of $14.66 and a 200 day moving average price of $11.17.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.